Therapeutic Antibodies: Methods and Protocols
With revenues from the top five therapeutic antibodies accounting for a majority of the recent pharmaceutical sales, the research and development in the field has exploded over the past several years and is expected to grow with new emerging monoclonal antibodies like Numax, Lucentis, Actemra, and o...
Gespeichert in:
Weitere Verfasser: | |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
Totowa, NJ
Humana Press
2009
|
Schriftenreihe: | Methods in Molecular Biology™, Methods and Protocols
525 |
Schlagworte: | |
Online-Zugang: | UBR01 TUM01 Volltext |
Zusammenfassung: | With revenues from the top five therapeutic antibodies accounting for a majority of the recent pharmaceutical sales, the research and development in the field has exploded over the past several years and is expected to grow with new emerging monoclonal antibodies like Numax, Lucentis, Actemra, and others. In Therapeutic Antibodies: Methods and Protocols, leading experts from academic laboratories and biotechnology companies present an extensive set of protocols for the discovery and development of therapeutic antibodies, featuring sections devoted to recombinant antigens, antibody libraries, antibody discovery, antibody engineering, and antibody preclinical development. Written in the highly successful Methods in Molecular Biology™ series format, the chapters contain brief introductions to their respective subjects, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes highlighting tips on troubleshooting and avoiding known pitfalls. Comprehensive and cutting-edge, Therapeutic Antibodies: Methods and Protocols serves as a key resource for researchers and antibody engineers investigating and participating in this rapidly growing therapeutic market segment |
Beschreibung: | 1 Online-Ressource (XVIII, 585 p) |
ISBN: | 9781597455541 |
DOI: | 10.1007/978-1-59745-554-1 |
Internformat
MARC
LEADER | 00000nmm a2200000zcb4500 | ||
---|---|---|---|
001 | BV044950745 | ||
003 | DE-604 | ||
005 | 00000000000000.0 | ||
007 | cr|uuu---uuuuu | ||
008 | 180517s2009 |||| o||u| ||||||eng d | ||
020 | |a 9781597455541 |9 978-1-59745-554-1 | ||
024 | 7 | |a 10.1007/978-1-59745-554-1 |2 doi | |
035 | |a (ZDB-2-PRO)978-1-59745-554-1 | ||
035 | |a (OCoLC)712419284 | ||
035 | |a (DE-599)BVBBV044950745 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
049 | |a DE-355 |a DE-91 | ||
082 | 0 | |a 616.079 |2 23 | |
245 | 1 | 0 | |a Therapeutic Antibodies |b Methods and Protocols |c edited by Antony S. Dimitrov |
264 | 1 | |a Totowa, NJ |b Humana Press |c 2009 | |
300 | |a 1 Online-Ressource (XVIII, 585 p) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
490 | 0 | |a Methods in Molecular Biology™, Methods and Protocols |v 525 | |
520 | |a With revenues from the top five therapeutic antibodies accounting for a majority of the recent pharmaceutical sales, the research and development in the field has exploded over the past several years and is expected to grow with new emerging monoclonal antibodies like Numax, Lucentis, Actemra, and others. In Therapeutic Antibodies: Methods and Protocols, leading experts from academic laboratories and biotechnology companies present an extensive set of protocols for the discovery and development of therapeutic antibodies, featuring sections devoted to recombinant antigens, antibody libraries, antibody discovery, antibody engineering, and antibody preclinical development. Written in the highly successful Methods in Molecular Biology™ series format, the chapters contain brief introductions to their respective subjects, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes highlighting tips on troubleshooting and avoiding known pitfalls. Comprehensive and cutting-edge, Therapeutic Antibodies: Methods and Protocols serves as a key resource for researchers and antibody engineers investigating and participating in this rapidly growing therapeutic market segment | ||
650 | 4 | |a Biomedicine | |
650 | 4 | |a Immunology | |
650 | 4 | |a Antibodies | |
650 | 4 | |a Medicine | |
650 | 4 | |a Immunology | |
650 | 4 | |a Antibodies | |
700 | 1 | |a Dimitrov, Antony S. |4 edt | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781934115923 |
856 | 4 | 0 | |u https://doi.org/10.1007/978-1-59745-554-1 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
912 | |a ZDB-2-PRO | ||
999 | |a oai:aleph.bib-bvb.de:BVB01-030343504 | ||
966 | e | |u https://doi.org/10.1007/978-1-59745-554-1 |l UBR01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
966 | e | |u https://doi.org/10.1007/978-1-59745-554-1 |l TUM01 |p ZDB-2-PRO |x Verlag |3 Volltext |
Datensatz im Suchindex
_version_ | 1804178538548428800 |
---|---|
any_adam_object | |
author2 | Dimitrov, Antony S. |
author2_role | edt |
author2_variant | a s d as asd |
author_facet | Dimitrov, Antony S. |
building | Verbundindex |
bvnumber | BV044950745 |
collection | ZDB-2-PRO |
ctrlnum | (ZDB-2-PRO)978-1-59745-554-1 (OCoLC)712419284 (DE-599)BVBBV044950745 |
dewey-full | 616.079 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 616 - Diseases |
dewey-raw | 616.079 |
dewey-search | 616.079 |
dewey-sort | 3616.079 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
doi_str_mv | 10.1007/978-1-59745-554-1 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02750nmm a2200445zcb4500</leader><controlfield tag="001">BV044950745</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">180517s2009 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781597455541</subfield><subfield code="9">978-1-59745-554-1</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-59745-554-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-PRO)978-1-59745-554-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)712419284</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044950745</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.079</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Therapeutic Antibodies</subfield><subfield code="b">Methods and Protocols</subfield><subfield code="c">edited by Antony S. Dimitrov</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XVIII, 585 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Methods in Molecular Biology™, Methods and Protocols</subfield><subfield code="v">525</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">With revenues from the top five therapeutic antibodies accounting for a majority of the recent pharmaceutical sales, the research and development in the field has exploded over the past several years and is expected to grow with new emerging monoclonal antibodies like Numax, Lucentis, Actemra, and others. In Therapeutic Antibodies: Methods and Protocols, leading experts from academic laboratories and biotechnology companies present an extensive set of protocols for the discovery and development of therapeutic antibodies, featuring sections devoted to recombinant antigens, antibody libraries, antibody discovery, antibody engineering, and antibody preclinical development. Written in the highly successful Methods in Molecular Biology™ series format, the chapters contain brief introductions to their respective subjects, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes highlighting tips on troubleshooting and avoiding known pitfalls. Comprehensive and cutting-edge, Therapeutic Antibodies: Methods and Protocols serves as a key resource for researchers and antibody engineers investigating and participating in this rapidly growing therapeutic market segment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomedicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibodies</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dimitrov, Antony S.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781934115923</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-59745-554-1</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-PRO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030343504</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-59745-554-1</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-59745-554-1</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
id | DE-604.BV044950745 |
illustrated | Not Illustrated |
indexdate | 2024-07-10T08:05:34Z |
institution | BVB |
isbn | 9781597455541 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030343504 |
oclc_num | 712419284 |
open_access_boolean | |
owner | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
owner_facet | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
physical | 1 Online-Ressource (XVIII, 585 p) |
psigel | ZDB-2-PRO |
publishDate | 2009 |
publishDateSearch | 2009 |
publishDateSort | 2009 |
publisher | Humana Press |
record_format | marc |
series2 | Methods in Molecular Biology™, Methods and Protocols |
spelling | Therapeutic Antibodies Methods and Protocols edited by Antony S. Dimitrov Totowa, NJ Humana Press 2009 1 Online-Ressource (XVIII, 585 p) txt rdacontent c rdamedia cr rdacarrier Methods in Molecular Biology™, Methods and Protocols 525 With revenues from the top five therapeutic antibodies accounting for a majority of the recent pharmaceutical sales, the research and development in the field has exploded over the past several years and is expected to grow with new emerging monoclonal antibodies like Numax, Lucentis, Actemra, and others. In Therapeutic Antibodies: Methods and Protocols, leading experts from academic laboratories and biotechnology companies present an extensive set of protocols for the discovery and development of therapeutic antibodies, featuring sections devoted to recombinant antigens, antibody libraries, antibody discovery, antibody engineering, and antibody preclinical development. Written in the highly successful Methods in Molecular Biology™ series format, the chapters contain brief introductions to their respective subjects, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes highlighting tips on troubleshooting and avoiding known pitfalls. Comprehensive and cutting-edge, Therapeutic Antibodies: Methods and Protocols serves as a key resource for researchers and antibody engineers investigating and participating in this rapidly growing therapeutic market segment Biomedicine Immunology Antibodies Medicine Dimitrov, Antony S. edt Erscheint auch als Druck-Ausgabe 9781934115923 https://doi.org/10.1007/978-1-59745-554-1 Verlag URL des Erstveröffentlichers Volltext |
spellingShingle | Therapeutic Antibodies Methods and Protocols Biomedicine Immunology Antibodies Medicine |
title | Therapeutic Antibodies Methods and Protocols |
title_auth | Therapeutic Antibodies Methods and Protocols |
title_exact_search | Therapeutic Antibodies Methods and Protocols |
title_full | Therapeutic Antibodies Methods and Protocols edited by Antony S. Dimitrov |
title_fullStr | Therapeutic Antibodies Methods and Protocols edited by Antony S. Dimitrov |
title_full_unstemmed | Therapeutic Antibodies Methods and Protocols edited by Antony S. Dimitrov |
title_short | Therapeutic Antibodies |
title_sort | therapeutic antibodies methods and protocols |
title_sub | Methods and Protocols |
topic | Biomedicine Immunology Antibodies Medicine |
topic_facet | Biomedicine Immunology Antibodies Medicine |
url | https://doi.org/10.1007/978-1-59745-554-1 |
work_keys_str_mv | AT dimitrovantonys therapeuticantibodiesmethodsandprotocols |